CD8+ TILs/CD4+CD25+FOXP3+ Treg ratio was associated with survival of patients with ESCC (5‐year OS: high vs. low: 75.3% vs. 56.2%, p = 0.0233, Figure 1J). This evidence concerns the gene FOXP3 and esophageal squamous cell carcinoma.